Stoke Therapeutics, INC Form 4 insider transactions

Barry Ticho, CHIEF MEDICAL OFFICER of Stoke Therapeutics, Inc., sold 7,176 shares of common stock on August 3, 2026.

Seth Loring Harrison, a Director of Stoke Therapeutics, Inc., reported multiple transactions in common stock on July 16, 2026.

Thomas Mccauley, Chief Scientific Officer of Stoke Therapeutics, Inc., received 225,000 shares of common stock on July 15, 2026.

Stoke Therapeutics Chief Medical Officer Barry Ticho sold a total of 7,228 shares of common stock in multiple transactions executed under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics General Counsel & Corp Sec, Jonathan Allan, reported a sale of 1,457 common shares on June 16, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Arthur Tzianabos was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Director Julie Smith was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Director Arthur A. Levin was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Director Adrian R. Krainer was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Director Edward M. Kaye was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard compensation.

Director Seth Loring Harrison was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard compensation.

Director Jennifer Burstein was granted 17,786 stock options in Stoke Therapeutics, Inc. as part of standard equity compensation.

Chief Medical Officer Barry Ticho sold 1,795 shares of Stoke Therapeutics common stock via a pre-arranged 10b5-1 plan.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc., reported a transaction involving the sale of common stock executed under a Rule 10b5-1 trading plan.

Clare Kahn, a Director at Stoke Therapeutics, Inc., acquired stock options for 30,782 shares.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, Inc., reported a transaction involving the sale of 1,838 shares of common stock on April 1, 2026, executed under a Rule 10b5-1 trading plan.

Stoke Therapeutics General Counsel Jonathan Allan sold 9,293 shares of common stock on March 20, 2026, under a pre-arranged 10b5-1 trading plan.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported multiple sales of common stock, including tax-related withholdings and transactions under a 10b5-1 plan.

Stoke Therapeutics CFO Thomas Leggett sold common stock totaling 4,578 shares to cover tax withholding liabilities related to restricted stock unit vesting.

Stoke Therapeutics' Chief Patient Officer, Jason Hoitt, sold common stock to cover tax liabilities from restricted stock unit vesting.

Stoke Therapeutics' General Counsel, Jonathan Allan, reported the sale of 8,895 common shares to cover tax withholding liabilities from restricted stock unit vesting.

Stoke Therapeutics' Chief Patient Officer, Jason Hoitt, converted 10,000 restricted stock units into common stock on March 15, 2026.

Stoke Therapeutics' Chief Financial Officer, Thomas Leggett, acquired 14,750 shares of common stock through the vesting of restricted stock units.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported the vesting and acquisition of 33,850 shares of common stock through Restricted Stock Units.

Stoke Therapeutics Director Edward M. Kaye exercised restricted stock units, increasing his direct beneficial ownership of common stock.

Stoke Therapeutics General Counsel Jonathan Allan reported the acquisition of common stock through RSU vesting and an Employee Stock Purchase Plan.

Stoke Therapeutics Director Arthur A. Levin sold 605 shares of common stock for $36.80 per share under a pre-arranged 10b5-1 trading plan.

Stoke Therapeutics' Interim Executive Chair, Arthur Tzianabos, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Stoke Therapeutics Director Adrian R. Krainer reported the sale of 33,243 shares of common stock at a weighted average price of $39.7366 per share.

Stoke Therapeutics Director Adrian R. Krainer sold 7,229 shares of common stock for approximately $286,700 under a pre-arranged trading plan.